The US research involved 73 people with rare mutations that cause an overproduction of toxic amyloid protein in the brain.
This meant they were all but guaranteed to develop the condition by middle age between their 30s and 50s.
Patients were injected with the antibody drug, gantenerumab, every two weeks, according to the study in the Lancet Neurology journal.
Decades
In a subgroup of 22 people who took the drug for the longest - an average of eight years - the risk of developing symptoms f...
This meant they were all but guaranteed to develop the condition by middle age between their 30s and 50s.
Patients were injected with the antibody drug, gantenerumab, every two weeks, according to the study in the Lancet Neurology journal.
Decades
In a subgroup of 22 people who took the drug for the longest - an average of eight years - the risk of developing symptoms f...
You're reading a preview of
Daily Express (Digital) - 1 Issue, March 20, 2025